Indonesian paint manufacturer PT Mowilex is safeguarding workers’ health by purchasing Covid-19 diagnostic tests from U.S. health care company Abbott. PT Mowilex will roll out an aggressive testing program to enhance distancing and hygiene protocols it adopted in early March 2020.

“We have had several short, voluntary closures of our head office and manufacturing facilities in the last two months and wanted to make sure our employees have access to one of the best rapid testing technologies available on the market,” said Syahrudin Rasjid, Head of Human Resources at PT Mowilex.

PT Mowilex selected Abbott among many test suppliers because Abbott’s tests offer very high accuracy. The Panbio Covid-19 Ag Rapid tests purchased by Mowilex are based on nasopharyngeal swabs and have a role in detecting active infections.

Panbio Covid-19 Ag is CE-Marked and has received WHO Emergency Use Listing (EUL). To date, Abbott has launched eight Covid-19 tests globally, including lab-based and rapid molecular tests, and antibody tests. Abbott has delivered more than 300 million Covid-19 tests worldwide.

“Abbott is one of the leading healthcare companies in the world and has received WHO Emergency Use Listing for its Panbio Covid-19 Ag Rapid tests. We are proud to partner with such a respected organization, and we’ve been impressed with the company’s responsiveness,” said PT Mowilex CEO Niko Safavi.